Patients who received ipilimumab as adjuvant therapy had improved recurrent-free survival, but also high rates of toxicity.
Researchers interpreting results from studies using adaptive randomization must be aware of assumptions made during study.
This chronic myeloid leukemia (CML) model may help direct treatment for patients in the future.
Some health care insurers have stopped covering this FDA-approved genetic test, instead limiting coverage only for cheaper, lower-quality genetic tests.
Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Insurance Plans Dropping Coverage of FDA-approved BRCA Diagnostic Test
- Genomic Information and the Future of Health Care
- Lartruvo (Olaratumab) Offers New Promise for Patients With Soft Tissue Sarcoma
- Less Frequent Cervical Cancer Screenings May Be Okay After HPV Vaccine
- Landmark Approval for First-line Sarcoma Therapy
- Weighing the Benefits Against the Toxicities of Ipilimumab in Melanoma
- Watch the updated FASLODEX® (fulvestrant) MOA video to see how FASLODEX can help you target the ER
- Study Affirms Activity of Nivolumab in Heavily Pretreated Classical Hodgkin Lymphoma
- Localized Consolidative Therapy May Be Effective in Oligometastatic NSCLC
- Adaptive Randomization and the I-SPY 2 Trial Platform